$CHRO
Channel Therapeutics Corp Stock $chro

$chro Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000175392624000740 Filed on April 16, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue		$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$1.585M	$4.283M
YoY Change		293.79%	122.33%
% of Gross Profit
Research & Development	$12.96K	$2.294M	$2.579M
YoY Change	-74.09%	678.75%	558.52%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.764M	$3.879M	$6.862M
YoY Change	126.98%	456.5%	196.02%
Operating Profit	-$1.764M		-$6.862M
YoY Change	126.99%		196.02%
Interest Expense		-$160.3K	-$518.5K
YoY Change		276.38%	269.31%
% of Operating Profit
Other Income/Expense, Net	-$7.533K		-$518.5K
YoY Change	-95.72%		269.23%
Pretax Income	-$1.772M	-$4.039M	-$7.381M
YoY Change	85.82%	446.13%	200.2%
Income Tax
% Of Pretax Income
Net Earnings	-$1.772M	-$4.039M	-$7.381M
YoY Change	85.82%	446.13%	200.2%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.31		$5.78
Diluted Earnings Per Share		-$0.70	-$1.28
COMMON SHARES
Basic Shares Outstanding	5.878M shares		1.277M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments		$96.39K	$96.39K
YoY Change		75.25%	74.94%
Cash & Equivalents	$2.405M	$100.0K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses	$158.1K
Receivables
Other Receivables
Total Short-Term Assets	$2.604M	$96.39K	$96.39K
YoY Change	3075.12%	75.26%	74.94%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$2.604M	$96.39K	$96.39K
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$2.604M	$96.39K	$96.39K
YoY Change	3075.12%	75.26%	74.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$4.626M	$4.626M
YoY Change		54.26%	54.25%
Accrued Expenses	$363.4K	$645.9K	$646.0K
YoY Change	-19.6%	190.97%	191.1%
Deferred Revenue
YoY Change
Short-Term Debt		$1.269M	$1.269M
YoY Change		134.94%	134.77%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.786M	$6.541M	$6.541M
YoY Change	-44.09%	73.87%	73.89%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.786M	$6.541M	$6.541M
Total Long-Term Liabilities		$0.00	$0.00
Total Liabilities	$2.786M	$6.541M	$6.541M
YoY Change	-44.09%	73.87%	73.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.85M	-$13.52M
YoY Change		120.23%
Common Stock	$584.00	$391.00
YoY Change		252.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$182.5K	-$6.445M	-$6.445M
YoY Change
Total Liabilities & Shareholders Equity	$2.604M	$96.39K	$96.39K
YoY Change	3075.12%	75.26%	74.94%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.772M	-$4.039M	-$7.381M
YoY Change	85.82%	446.13%	200.2%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		-$356.8K	-$981.0K
YoY Change		-46.48%	-37.4%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		430.5K	$1.022M
YoY Change		-21.51%	-36.98%
NET CHANGE
Cash From Operating Activities		-356.8K	-$981.0K
Cash From Investing Activities
Cash From Financing Activities		430.5K	$1.022M
Net Change In Cash		73.62K	$41.32K
YoY Change		-162.23%	-24.88%
FREE CASH FLOW
Cash From Operating Activities		-$356.8K	-$981.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Other Loans Payable OtherLoansPayable		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	chro	Stock Issued During Period Value Share Based Compensation Forfeited Value StockIssuedDuringPeriodValueShareBasedCompensationForfeitedValue		usd
CY2022	chro	Issuance Cost From Shares Issued On Extension Of Bridge Loan IssuanceCostFromSharesIssuedOnExtensionOfBridgeLoan		usd
CY2022	chro	Shares Issued For License SharesIssuedForLicense		usd
CY2023	chro	Due To Parent DueToParent		usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
CY2023	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt		usd
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
CY2023	chro	Net Contribution From Chromocell Corporation NetContributionFromChromocellCorporation		usd
CY2023	chro	Advance From Chromocell Corporation AdvanceFromChromocellCorporation		usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	chro	Fair Value Of Shares Issued In Contribution Agreement FairValueOfSharesIssuedInContributionAgreement		usd
CY2022	chro	Debt Discount From Shares Issued On Extension Of Bridge Loan DebtDiscountFromSharesIssuedOnExtensionOfBridgeLoan		usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
CY2022Q4	chro	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingLife	P9Y9M3D
CY2023	chro	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Remaining Life ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingLife	P9Y1M27D
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q4	chro	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingLife	P9Y0M29D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y11M23D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares		shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
CY2023	chro	Weighted Average Period For The Unamortized Stock Compensation WeightedAveragePeriodForTheUnamortizedStockCompensation	P2Y10M28D
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential		pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential		pure
CY2022Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent		usd
CY2022Q4	chro	Deferred Capitalized Intellectual Property Costs DeferredCapitalizedIntellectualPropertyCosts		usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1857206	usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	0	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5877835	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	Houston, Texas
CY2023Q4	us-gaap	Cash Cash	96391	usd
CY2022Q4	us-gaap	Cash Cash	55074	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3914338	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3914338	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1111112	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1111112	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	391	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	111	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7074646	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2432148	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13519649	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6138856	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-6444552	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3706537	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	96391	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55074	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2738948	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1098848	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2579418	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	391730	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	1543918	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	827581	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	6862284	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	2318159	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-6862284	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2318159	usd
CY2023	chro	Interest Expense On Promissory Note Related Party InterestExpenseOnPromissoryNoteRelatedParty	518509	usd
CY2022	chro	Interest Expense On Promissory Note Related Party InterestExpenseOnPromissoryNoteRelatedParty	140430	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-518509	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-7380793	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2458589	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7380793	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2458589	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.78
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.65
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1276543	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	435312	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3680267	usd
CY2022	chro	Fair Value Of Shares Issued In Contribution Agreement FairValueOfSharesIssuedInContributionAgreement	1900000	usd
CY2022	chro	Net Contributions From Chromocell Corporation NetContributionsFromChromocellCorporation	422173	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	110146	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2458589	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3706537	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1733233	usd
CY2023	chro	Shares Issued For Extension Of Bridge Loan SharesIssuedForExtensionOfBridgeLoan	428400	usd
CY2023	chro	Stock Issued During Period Shares Issued For License StockIssuedDuringPeriodSharesIssuedForLicense	2225733	usd
CY2023	chro	Shares Issued For Cash SharesIssuedForCash	255412	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-6444552	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7380793	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2458589	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	188119	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	140430	usd
CY2023	chro	Issuance Cost From Shares Issued On Extension Of Bridge Loan IssuanceCostFromSharesIssuedOnExtensionOfBridgeLoan	201600	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1733233	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	110146	usd
CY2023	chro	Shares Issued For License SharesIssuedForLicense	-2225733	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1627005	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	413603	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	424072	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	221875	usd
CY2022	chro	Due To Parent DueToParent	5386	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-981031	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1567149	usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	201008	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	565928	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	100000	usd
CY2022	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	300000	usd
CY2023	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	255412	usd
CY2022	chro	Net Contribution From Chromocell Corporation NetContributionFromChromocellCorporation	422173	usd
CY2022	chro	Advance From Chromocell Corporation AdvanceFromChromocellCorporation	800050	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1022348	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1622223	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	41317	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	55074	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55074	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96391	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55074	usd
CY2022	chro	Fair Value Of Shares Issued In Contribution Agreement FairValueOfSharesIssuedInContributionAgreement	1900000	usd
CY2023	chro	Debt Discount From Shares Issued On Extension Of Bridge Loan DebtDiscountFromSharesIssuedOnExtensionOfBridgeLoan	428400	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	13	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_805_eus-gaap--NatureOfOperations_zP3t9aZqnPa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>NOTE 1 – <span id="xdx_82A_z0Fp29OTPOK2">ORGANIZATION AND NATURE OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Company Background </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chromocell Therapeutics Corporation (“Chromocell” or the “Company”) was incorporated in the State of Delaware on March 19, 2021. On August 10, 2022, the Company entered into that certain Contribution Agreement (the “Contribution Agreement”) with Chromocell Corporation, a Delaware corporation (“Chromocell Holdings”), pursuant to which, effective July 12, 2022 (the “Contribution Date”), Chromocell Holdings contributed all assets and liabilities related to Chromocell Holdings’ historical therapeutic business, including all patents, pre-clinical and Phase I study results and data, and trade secrets related to the CC8464 compound to the Company. (See Note 4)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company is a development stage life sciences company which improves consumer products and patient lives through breakthrough science and technologies. The Company is focused on the discovery and development of therapeutics through the use of pioneering Chromovert® technology. Chromovert technology enables the Company to use rare cells ideally suited for effective high-throughput screening. The Company’s therapeutics pipeline is currently focused on analgesics and rare diseases, where Chromovert technology has proven highly effective in the rapid identification of potential new drug candidates. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company has a limited operating history and has not generated revenue from its intended operations. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal governmental policy decisions. A host of factors beyond the Company’s control could cause fluctuations in these conditions. Adverse conditions may include changes in the biotechnology regulatory environment, technological advances that render our technologies obsolete, availability of resources for clinical trials, acceptance of technologies into the medical community, and competition from larger, more well-funded companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On January 30, 2020, the World Health Organization declared the COVID-19 novel coronavirus outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 coronavirus and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. On May 11, 2023, the United States government declared an end to the COVID-19 pandemic, but it is reasonably possible that future capital raising efforts and additional development of our technologies may still be negatively affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 21, 2024, <span id="xdx_906_eus-gaap--SaleOfStockDescriptionOfTransaction_c20240219__20240221_zxK2lmiqxbk3" title="Sale of stock, description of transaction">the Company completed the initial public offering of its Common Stock (the “IPO”) and issued and sold <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20240221_zxlJQI80fZ65" title="Issued and sold shares of Common Stock">1,100,000</span> shares of Common Stock at a price to the public of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20240221_zst84mCx60Ag" title="Common stock price (per share)">6.00</span> per share. The aggregate net proceeds from the IPO were approximately $5.7 million after deducting underwriting discounts and commissions and offering expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
CY2024Q1	us-gaap	Sale Of Stock Description Of Transaction SaleOfStockDescriptionOfTransaction	the Company completed the initial public offering of its Common Stock (the “IPO”) and issued and sold 1,100,000 shares of Common Stock at a price to the public of $6.00 per share. The aggregate net proceeds from the IPO were approximately $5.7 million after deducting underwriting discounts and commissions and offering expenses.
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1100000	shares
CY2024Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	6.00
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7380793	usd
CY2023Q4	us-gaap	Cash Cash	96391	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100000	usd
CY2023Q4	chro	Working Capital Deficit WorkingCapitalDeficit	6400000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100000	usd
CY2022Q4	chro	Working Capital Deficit WorkingCapitalDeficit	3700000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_z9VOg5DnY8Sh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_zDDuEf35O2Z3">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, realization of long-lived assets, valuation of deferred income taxes, unrealized tax positions and business combination accounting.</p>
CY2023	chro	Disaggregation Of R And D Expenses DisaggregationOfRAndDExpenses	<p id="xdx_89C_ecustom--DisaggregationOfRAndDExpenses_zpinXvKdaRch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><span id="xdx_8B0_z8233PGEieZ6">Below is a disaggregation of R&D expenses:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Consultant</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--ConsultantMember_zH8tc7BVIfze" style="width: 12%; text-align: right" title="Research and development expense">68,900</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--ConsultantMember_zARmc824HPta" style="width: 12%; text-align: right" title="Research and development expense">86,802</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lab Gas</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--LabGasMember_zUbqB6W7Xq7" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--LabGasMember_zCmlIsXvuTe1" style="text-align: right">13,871</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lab Cell Storage</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--LabCellStorageMember_zn4Xxge47bc3" style="text-align: right">48,572</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--LabCellStorageMember_zLCquzwaw8V" style="text-align: right">62,197</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Chemistry Manufacturing and Controls (“CMC”)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--ChemistryManufacturingAndControlsMember_zCYkEkZkxksh" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--ChemistryManufacturingAndControlsMember_zoOty4wIwdZg" style="text-align: right">3,800</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">IP Services</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--IPServicesMember_zGPAg0Wsr36g" style="border-bottom: Black 1pt solid; text-align: right">2,461,946</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--IPServicesMember_zuW202HxuvFi" style="border-bottom: Black 1pt solid; text-align: right">225,060</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231_zWctlD3JMmj6" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense">2,579,418</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_z4Yf9iAgl7Ni" style="border-bottom: Black 2.5pt double; text-align: right" title="Research and development expense">391,730</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2579418	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	391730	usd
CY2023Q1	chro	Employment Agreement Description EmploymentAgreementDescription	Pursuant to such agreement, Mr. Kopfli agreed to serve as the Company’s Chief Executive Officer and Vice-Chairman of its Board of Directors (the “Board”) in consideration for an annualized salary of $275,000, payable in cash at the rate of $5,000 per month (a minimum of $1,125 per week), with the remainder accrued and paid as of the earliest of a sale or liquidation of the Company, the Company’s bankruptcy or three days after the approval by the Board of a funded budget with appropriately established milestones subsequent to the effective date of a Form S-1 registration statement (“Post-registration Approval”). Mr. Kopfli also agreed, as of Post-registration Approval, to resign as Chief Executive Officer of Chromocell Corporation although he may continue service on the Board of Directors of Chromocell Corporation, including as its Board Chairperson. The employment agreement provides that Mr. Kopfli receive an option to acquire 22,223 shares of the Company’s common stock
CY2024Q1	chro	Demand Letter From Attorney Description DemandLetterFromAttorneyDescription	the Board received a demand letter from an attorney representing Chromocell Holdings and Mr. Kopfli. Mr. Kopfli alleges an improper termination for “cause” and seeks monetary damages in connection therewith in the amount of $479,169. Of the $479,169 asserted by Mr. Kopfli, as of December 31, 2023, the Company has accrued $363,091 in compensation expenses associated with Mr. Kopfli’s prior employment with the Company. To the extent Mr. Kopfli is successful in his assertions, the Company will pay any amounts owed thereunder from future working capital reserves; however, the Company believe the assertions made by Mr. Kopfli are without merit and intend to vigorously defend the matter.
CY2022Q4	chro	Director Note Description DirectorNoteDescription	the Company and Mr. Todd Davis, one of the Company’s directors, entered into the Director Note for $175,000. The Director Note has an original issuance discount of $75,000, and matures on December 31, 2023, or, if earlier to occur, upon the closing of an underwritten offering of securities resulting in at least $15 million in gross proceeds.
CY2023Q4	chro	Due To Chromocell Corporation DueToChromocellCorporation	5386	usd
CY2023Q3	chro	Side Letter To The Contribution Agreement SideLetterToTheContributionAgreement	the Company entered into a side letter to the Contribution Agreement (the “Holdings Side Letter”) with Chromocell Holdings. Pursuant to the side letter, upon closing of the Company’s IPO: (a) Chromocell Holdings re-assumed all $1.6 million in direct liabilities previously assumed by the Company in accordance with the Contribution Agreement, (b) Chromocell Holdings waived the Company’s obligations to make a cash payment in the amount of $0.6 million to Chromocell Holdings, and (c) in consideration thereof, the Company issued to Chromocell Holdings 2,600 shares of Series C Convertible Redeemable Preferred Stock of the Company, par value of $0.0001 per share (the “Series C Preferred Stock”).
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	11112	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	22.68
CY2022Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	450000	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	150000	usd
CY2022Q1	us-gaap	Investment Interest Rate InvestmentInterestRate	0.50	pure
CY2022Q1	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-02-03
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	14370	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	135630	usd
CY2023Q1	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	the Investor Note agreement was amended. The maturity date was extended from its original due date of February 3, 2023 to May 15, 2023, in return for the Company agreeing to pay 2% per month in accrued interest and the third party agreeing to settle its outstanding debt, including accrued interests in shares of common stock at the IPO. Accrued interest and related interest expense totaled $98,056 for the years ended December 31, 2023, compared to $0 for year ended December 31, 2022.
CY2023Q2	us-gaap	Debt Conversion Description DebtConversionDescription	in consideration therefor, issued to such holder 50,000 shares of common stock. The Company determined that this extension qualified as a modification of the Investor Note rather than an extinguishment. The Company recorded an expense of $126,000 from the issuance of the 556 shares of common stock based on a share price of $22.68. The $22.68 share price was based on a third-party valuation of the company’s common stock, with certain adjustments as set forth below in detail in Note 7 – Stockholders’ Equity. This expense was recorded to interest expense on the Company’s statement of operations for the year ended December 31, 2023.
CY2023Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	1203704	shares
CY2023	us-gaap	Sale Of Stock Description Of Transaction SaleOfStockDescriptionOfTransaction	in consideration therefor, the Company would issue upon close of the IPO, and regardless of whether the Company would have issued any shares of Series B Preferred Stock, an aggregate of 4,167 shares (such shares, the “Standby Shares”) of Common Stock to the Standby Investor (such agreement, the “Series B Securities Purchase Agreement”).
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44800000	usd
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1187302	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	37.71
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44800000	usd
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1187302	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	37.71
CY2022Q3	chro	Illiquidity Discount IlliquidityDiscount	20	pure
CY2022Q3	chro	Minority Discount MinorityDiscount	20	pure
CY2022Q3	chro	Fair Value Of Common Stock Per Share FairValueOfCommonStockPerShare	22.68
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	50002	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.68
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	158670	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	22.68
CY2023Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	22016	usd
CY2023Q4	chro	Deferred Capitalized Intellectual Property Costs DeferredCapitalizedIntellectualPropertyCosts	620440	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	36202	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3626571	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1857206	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3626571	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	197560	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.68
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	84131	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	22.68
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	45556	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	22.68
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	158670	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	22.68
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	90797	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	22.68
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	113429	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	22.68
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	197560	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	22.68
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1733233	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	110146	usd
CY2023	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1854280	usd
CY2023Q2	us-gaap	Business Acquisition Equity Interest Issued Or Issuable Description BusinessAcquisitionEquityInterestIssuedOrIssuableDescription	the Company and Camden Capital LLC amended and restated the Consultant Agreement by entering into an Amended and Restated Consultant Agreement, whereby the RSU for 16,667 shares of common stock was cancelled, and the Company agreed to grant Camden Capital LLC an option to acquire 27,778 shares of common stock within 30 days of the closing of the IPO. As of June 23, 2023, such RSU for 16,667 shares of common stock had not vested, and no expense was recorded on the Company’s financial statements.
CY2023Q4	chro	Benuvia License Agreement Description BenuviaLicenseAgreementDescription	the Company agreed to pay Benuvia a 6.5% royalty on net sales of the Spray Formulations for a period of up to 15 years from the date of the first commercial sale of any of the Spray Formulations. In addition, on December 23, 2023, the Company entered into a stock issuance agreement with Benuvia pursuant to which the Company agreed to issue Benuvia 384,226 shares of the Company’s Common Stock.
CY2023	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	384226	shares
CY2023	us-gaap	Entertainment License Agreement For Program Material Amortization Expense EntertainmentLicenseAgreementForProgramMaterialAmortizationExpense	2200000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.1911	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.1911	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0900	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0900	pure
CY2023	chro	Valuation Allowance ValuationAllowance	-0.2811	pure
CY2023	chro	Valuation Allowance ValuationAllowance	-0.2811	pure
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	2248163	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	1763875	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	518174	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	30962	usd
CY2023Q4	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	181576	usd
CY2022Q4	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	62369	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1857206	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	8000000.0	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	8000000.0	usd

Files In Submission

Name	View Source	Status
0001753926-24-000740-index-headers.html	Edgar Link	pending
0001753926-24-000740-index.html	Edgar Link	pending
0001753926-24-000740.txt	Edgar Link	pending
0001753926-24-000740-xbrl.zip	Edgar Link	pending
chro-20231231.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g084167_10k.htm	Edgar Link	pending
g084167_ex19-1.htm	Edgar Link	pending
g084167_ex23-1.htm	Edgar Link	pending
g084167_ex3-3.htm	Edgar Link	pending
g084167_ex31-1.htm	Edgar Link	pending
g084167_ex31-2.htm	Edgar Link	pending
g084167_ex32-1.htm	Edgar Link	pending
g084167_ex32-2.htm	Edgar Link	pending
g084167_ex4-2.htm	Edgar Link	pending
g084167_ex97-1.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
chro-20231231_cal.xml	Edgar Link	unprocessable
chro-20231231_def.xml	Edgar Link	unprocessable
chro-20231231_lab.xml	Edgar Link	unprocessable
chro-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
g084167_10k_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CHRO
Channel Therapeutics Corp Stock $chro

2024 Q2 Form 10-K Financial Statement

#000175392624000740 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHRO Channel Therapeutics Corp Stock $chro

2024 Q2 Form 10-K Financial Statement

#000175392624000740 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHRO
Channel Therapeutics Corp Stock $chro